

## VITAL CARE RX GI Enrollment Form

Phone: (877)229-1724 | Fax: (877)229-1725

PATIENT INFORMATION  (Complete the following or send patient demographic sheet.)  Please fax copy of patient's insurance card including both sides			PRESCRIBER INFORMATION			
Name:			Prescriber Name:			
Mame	e:	NA / 5 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	State Lic. #:			
DOB:Gender: M / F Height:Wt:			Facility Name:			
			Address:			
City, State, Zip:			City, State, Zip:			
Home Phone:			Phone:	Fax	::	
Alternate Phone:			Contact:			
Last 4 digits SS#: Email: Phone:Email					:	
	Crohn's disease NOS	AL INFORMATION – STATEM  K51.90 Ulcerative Colitis  treatments and treatment duration	Other:	<u>ITY</u>	_	
Please indicate current or previous treatments and treatment duration below:  NSAIDS Duration: Corticosteroids Duration:						
	trovato Duration:		_			
Methotrexate Duration:				uration:		
Sulfasalazine Duration:				Duration:		
□ 6 – MP Duration: □ Other: Duration:						
Other medications patient is currently taking:  TB/PPD Test given?						
BSA: Expected date of first/next dose: Date of last dose:						
	-	PRESCRIPTION INFO				
Medication	tion <u>Directions</u>				Quantity	<u>Refills</u>
Cimzia®	☐ Starter Kit ☐ Initial dose: Inject 400 mg SC at we		eek 0 week 2 and week 4		1 starter kit	0
	☐ Prefilled Syringe☐ Lyophilized Powder		Maintenance dose: Inject 400 mg SC every 4 weeks		28 day supply	
Entyvio®	☐ 300 mg vial	☐ Initial Dose: Infuse 300mg IV over 30 minutes at week 0, week 2 and week 6 ☐ Maintenance dose: Infuse 300mg IV over 30 minutes every 8 weeks			Initial dose QS	
Humira®	☐ Starter Kit ☐ 40 mg Pen ☐ 40 mg PFS ☐ Starter Kit CF ☐ Initial Dose: Inject 160 mg SC on day 1, 80 mg on day 15, then 40 mg thereafter beginning on day 29			1 starter kit	0	
	☐ 40 mg CF Pen☐ 40 mg CF Prefilled Syringe	☐ Inject 40 mg SC once a week			28 day supply	
Remicade®	□ 100 mg vial	☐ Initial Dose: Infusemg/kg (mg) IV at weeks 0, 2, and 6 weeks. ☐ Maintenance Dose: Infusemg/kg (mg) IV everyweeks.			QS	
Rinvoq®	☐ Starter Kit: 45 mg	☐ Initial Dose: Take 45mg po once a d			28	1
	□ 15 mg □ 30 mg	☐ Maintenance Dose: Take 15mg po☐ Maintenance Dose: Take 30mg po	once a day.		30	
Simponi®	☐ 100 mg SmartJect☐ 100 mg PFS	☐ Initial Dose: Inject 200mg SC at week 0, then 100mg at week 2, then maintenance dose ☐ Maintenance Dose: Inject 100mg SC once every 4 weeks			3 units 28 day supply	0
Stelara®	☐ 130 mg vial	Initial Dose: Infuse IV over at least 1 hour. $\square \le 121$ lbs 260 mg (2 vials) $\square > 121$ lbs to 187 lbs 390 mg (3 vials) $\square > 187$ lbs 520 mg (4 vials)		QS	0	
	☐ 90mg Prefilled Syringe	☐ Maintenance Dose: Inject 90 mg SC 8 weeks after initial IV infusion, then every 8 weeks thereafter		QS		
Skyrizi®	☐ 600 mg vial	☐ Initial Dose: Infuse 600 mg IV over	at least 1 hour on week 0, 4 and 8.		1	2
	☐ 360 mg PF on-body injector	☐ Maintenance Dose: Inject 360 mg SC at week 12, and every 8 weeks thereafter.			1	
Xeljanz®	☐ 5 mg tabs ☐ 10 mg tabs	☐ Initial Dose: Take 10 mg PO BID for 8 weeks ☐ Maintenance Dose: Take 5 mg PO BID ☐ Maintenance Dose: Take 10 mg PO BID				
Xifaxan®	☐ 550mg Tablet	☐ Take 1 tablet by mouth 3 times a day			42	0
7enosia®	☐ 7 Day Titration Pack	☐ Initial Dose: Take as directed on titration pack. ☐ Maintenance Dose: Take 1 capsule by mouth once a day beginning day 8.			1 30	
Other:		and a supported by	, a way weginning ady or			
					Yes 🔲	No
Prescriber Signature  Date  Brand Name Required?  Yes  I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms, financial treatment and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of this product to another pharmacy of the patient's choice or in the						

patient's insurer's provider network.